ciglitazone has been researched along with Local Neoplasm Recurrence in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Excerpt | Relevance | Reference |
---|---|---|
"Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy." | 2.43 | Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment. ( Angelos, P; Sturgeon, C, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sturgeon, C | 1 |
Angelos, P | 1 |
1 review available for ciglitazone and Local Neoplasm Recurrence
Article | Year |
---|---|
Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Cisplat | 2006 |